Evogene (EVGN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Evogene (EVGN) is down 46.4% since the beginning of the year. At $1 per share, EVGN is trading 75.6% below its 52-week high of $2. Investors who bought $1,000 worth of EVGN shares 5 years ago would now be looking at an investment worth $17.

Evogene (EVGN) has returned -46.35% so far this year and -45.86% over the past 12 months. Over the last ten years, EVGN has returned -37.75% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Mar 5, 2008, EVGN's average daily return is +0.01%, while the average monthly return is -0.30%.

Historically, 36% of months were positive and 64% were negative. The best month was Aug 2020 with a return of +99.0%, while the worst month was Oct 2008 at -46.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 10 months.

On a daily basis, EVGN closed higher 30% of trading days. The best single day was Jun 10, 2025 with a return of +100.0%, while the worst single day was Oct 29, 2008 at -46.2%.

Evogene has an annualized alpha of -3.21%, beta of 0.45, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since March 06, 2008.

• This stock participated in 126.91% of S&P 500 Index downside but only 7.03% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.45 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

EVGN ranks 24 for risk / return — below 24% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Evogene (EVGN) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Evogene. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Evogene was 99.70%, occurring on Jun 2, 2026. The portfolio has not yet recovered.

The current Evogene drawdown is 99.70%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Evogene over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Evogene is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.